Annexin Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Annexin Pharmaceuticals is a Swedish privately held biotech company[1][2] developing new therapeutic approaches for inflammatory cardiovascular diseases. The concept for the therapy is based on the anti-inflammatory properties of Annexin A5, a body own protective protein that acts simultaneously against several key pathogenic mechanisms of cardiovascular diseases. The company is currently focusing on treatment of peripheral artery disease (PAD).

External links[edit]


  1. ^ Martz, Lauren (May 26, 2014). "Annexin: Attenuating vascular inflammation" (PDF). BioCentury: A18. Retrieved 1 February 2015. 
  2. ^